RT Journal Article
SR Electronic
T1 Safety of research bronchoscopy in asthma and COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA1396
DO 10.1183/13993003.congress-2016.PA1396
VO 48
IS suppl 60
A1 Patrick Mallia
A1 Maria-Belen Trujillo-Torralbo
A1 Jhaideep Dhariwal
A1 David Jackson
A1 Simon Message
A1 Joseph Footitt
A1 Sebastian Johnston
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA1396.abstract
AB Background: Fibre-optic bronchoscopy (FOB) is a research tool in asthma and COPD with a good safety record in stable patients. There is no data regarding adverse events for FOB in patients with asthma/COPD exacerbations.Aims: To evaluate the safety of FOB in subjects participating in experimental rhinovirus infection studies.Methods: We reviewed the records of these subjects from a single centre since 2000. Subjects had FOB at baseline and convalescence (stable) and during the virus-induced exacerbation (infection) with biopsies, brushings and BAL.Results: The clinical characteristics of the subjects are in Table 1 . There were no adverse events in the asthma studies and 3 in the COPD studies. Two subjects developed lower respiratory tract infections requiring antibiotics. In 1 subject (non-smoker) this occurred at the infection FOB and the subject was withdrawn. In the other subject (COPD) this occurred at the baseline FOB and he continued in the study and had 2 other uneventful FOB. One subject (smoker) had FOB terminated due to hypoxia.COPD studiesAsthma studiesNon-smokers (N=19)Smokers (N=29)COPD N=35Controls (N=40)Asthma (N=50)Total bronchoscopies386862109110Stable1940435950Infection1928195060Age58.95 (±1.59)52.10 (±1.41)59.51 (±1.11)28.30 (±1.65)31.60 (±1.54)Sex M:F9:1017:1222:1323:1716:21Smoking history/33.41 (±1.77)43.74 (±3.33)//FEV1 (litres)3.06 (±0.22)3.27 (±0.124)2.05 (±0.085)FEV1 %106 (±3.79)102 (±2.48)67.46 (±1.82)102.9 (±1.8)91.30 (±2.23)SABA only (%)//35/24 (48)ICS////26 (52)Mean ICS (BDP equivalent)////519 (±107.5)Clinical Characteristics of Study SubjectsConclusions: The incidence of adverse events in research FOB in asthma and COPD exacerbations is low.